Detalles de la búsqueda
1.
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Molecules;
28(24)2023 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38138547
2.
Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
Angiogenesis;
20(2): 233-241, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28389777
3.
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.
Cell Mol Life Sci;
69(7): 1167-78, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22130514
4.
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Cancer Res Commun;
3(3): 489-500, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36994441
5.
Differential angiogenesis of bone and muscle endothelium in aging and inflammatory processes.
Commun Biol;
6(1): 126, 2023 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36721025
6.
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells.
Oncoimmunology;
12(1): 2239035, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37538353
7.
Erratum to: Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.
Angiogenesis;
20(2): 243-244, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28488224
8.
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Mol Cancer Ther;
21(4): 555-567, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35149547
9.
PGC1α/ß Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer.
Cancer Res;
82(7): 1423-1434, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131872
10.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
J Hematol Oncol;
14(1): 186, 2021 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34742344
11.
A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing.
Elife;
82019 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30829570
12.
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium.
BMC Genomics;
9: 201, 2008 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-18447899
13.
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Clin Cancer Res;
9(9): 3476-85, 2003 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12960140
14.
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Mol Cancer Ther;
3(2): 111-21, 2004 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-14985451
15.
Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.
Oncotarget;
6(29): 28389-400, 2015 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26318044
16.
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Oncotarget;
6(5): 3043-54, 2015 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25460504
17.
Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.
Pigment Cell Melanoma Res;
28(1): 73-81, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25256553
18.
Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.
Cancer Res;
74(23): 6980-90, 2014 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25304260
19.
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.
Neoplasia;
14(9): 846-54, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23019416
20.
Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Oncotarget;
7(25): 38973, 2016 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770111